(Q53578107)

English

Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial.

scientific article published in April 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

quality of life

1 reference

based on heuristic

inferred from title

Benny Chung-Ying Zee

3

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

author name string

J Pater

1

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

D Osoba

2

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

W Lofters

4

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

M Gore

5

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

E Dempsey

6

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

M Palmer

7

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

C Chin

8

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

publication date

1 April 1998

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

Quality of Life Research

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

7

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

3

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

273-278

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

Quality of life studies in chemotherapy-induced emesis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9584558

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9584558

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9584558

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9584558

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9584558

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/9584558

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Instit

1 reference

https://pubmed.ncbi.nlm.nih.gov/9584558

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9584558

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methodology of antiemetic trials: a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/9584558

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/A:1008886200225

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/9584558

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53578107&oldid=1694372391"